Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer

PURPOSE: Immune checkpoint blockade (ICB) therapy has transformed the treatment of triple-negative breast cancer (TNBC) in recent years. However, some TNBC patients with high programmed death-ligand 1 (PD-L1) expression levels develop immune checkpoint resistance. Hence, there is an urgent need to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Ran, Wang, Yuhan, Fan, Jinyan, Tian, Ziyue, Wang, Shuang, Qin, Xiujuan, Su, Wei, Wang, Yanbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292819/
https://www.ncbi.nlm.nih.gov/pubmed/37377907
http://dx.doi.org/10.3389/fonc.2023.1108472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292819/
https://www.ncbi.nlm.nih.gov/pubmed/37377907
http://dx.doi.org/10.3389/fonc.2023.1108472

Ejemplares similares